← All diseases Liver, kidneys and digestion

Fatty liver disease (MASH/NASH), advanced

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (129)Meta-analysis (42)Randomized Trial (40)Systematic review (32)Phase 3 Study (15)Clinical research (223)Overview article (431)Early study (phase 1 or 2) (12)Laboratory or animal research (274)Single Patient Description (18)Commentary or Editorial (50)Retracted Publication (4) Studies currently seeking participants only (40)

Filter

Publications and studies (2550)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease (2024-12-20) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) (2024-12-19) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults (2024-12-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women (2024-11-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis (2024-11-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) (2024-11-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Usefulness of Ultrasound-derived Fat Fraction for Quantification of Hepatic Steatosis in Patients Suspected of MASLD (2024-10-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases (2024-10-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism (2024-09-23) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Positive Association of US-FLI With the Severity of CAD (2024-08-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients (2024-08-16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Ketogenic Diet in MASLD-related cACLD (2024-08-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD (2024-07-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease (2024-07-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes (2024-06-13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria (2024-06-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in MASLD (2024-06-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients (2024-06-05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Alpha-Glutathione-S-Transferase (AlphaGST) and MARINA Index in Metabolic-Dysfunction-Associated-Steatotic-Liver-Disease (MASLD) (2024-05-16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Risk of CKD in Diabetic Patients With MAFLD (2024-03-18) ♡
• Analysis of traditional Chinese medicine syndrome types and frequency changes of CD8+ and CD25+ T cells in metabolic-related fatty liver disease. (2023/12/31) ♡
• Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey. (2023/12/30) ♡
• Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models. (2023/12/29) ♡
• Maternal Weight Intervention in the Perinatal Period Improves Liver Health in the Offspring of Mothers with Obesity. (2023/12/28) ♡
• Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats (2023/12/28) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. (2023/12/27) ♡
• miR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1. (2023/12/26) ♡
• Collinsella aerofaciens linked with increased ethanol production and liver inflammation contribute to the pathophysiology of NAFLD. (2023/12/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [The role of apolipoprotein C3 in the regulation of nonalcoholic fatty liver disease, glucose and lipid metabolism, and islet β cell function]. (2023/12/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Diabetic Mellitus Patients in Saudi Arabia: Systematic Review and Meta-Analysis. (2023/12/25) ♡
• Tryptophan Prevents the Development of Non-Alcoholic Fatty Liver Disease. (2023/12/23) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. NASH/NAFLD-related Hepatocellular Carcinoma: An Added Burden. (2023/12/23) ♡
• Clinical profile, referral trends, and real-world application of vibration-controlled transient elastography in children with non-alcoholic fatty liver disease in Singapore. (2023/12/23) ♡
• Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study. (2023/12/22) ♡
• Clinical Management of Non-Alcoholic Steatohepatitis and the Role of the Cardiologist. (2023/12/22) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice (2023/12/22) ♡
• Identification and validation of key biomarkers associated with macrophages in nonalcoholic fatty liver disease based on hdWGCNA and machine learning. (2023/12/21) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sugar sweetened beverages, natural fruit juices, and cancer: what we know and what still needs to be assessed. (2023/12/21) ♡
• Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. (2023/12/21) ♡
• Frontiers and hotspots of adipose tissue and NAFLD: a bibliometric analysis from 2002 to 2022. (2023/12/21) ♡
• Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation. (2023/12/21) ♡
• Association of Dietary Acid Load with Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in US Adults: Evidence from NHANES 1999-2018. (2023/12/20) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. An Artificial Neural Network Model Combined with Dietary Retinol Intake from Different Sources to Predict the Risk of Nonalcoholic Fatty Liver Disease. (2023/12/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bioactive Compounds in Moringa oleifera: Mechanisms of Action, Focus on Their Anti-Inflammatory Properties. (2023/12/20) ♡
• [Doctors' original intentionality in adherence to non-invasive diagnoses benefits MAFLD patients]. (2023/12/20) ♡
• [Advances in serological non-invasive diagnosis for metabolic dysfunction-associated fatty liver disease]. (2023/12/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Research advances in the non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease based on magnetic resonance technology]. (2023/12/20) ♡
• [Application of omics in the diagnosis of metabolic dysfunction-associated fatty liver disease]. (2023/12/20) ♡
• [A study of the anti-fibrotic effect of ghrelin on mice with nonalcoholic steatohepatitis]. (2023/12/20) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Validating the Health Benefits of Coffee Berry Pulp Extracts in Mice with High-Fat Diet-Induced Obesity and Diabetes. (2023/12/20) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.